Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies

Executive Summary

Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.

Advertisement

Related Content

Deal Watch: Xencor Adds New Bispecific Partner In Agreement With Genentech
Aurinia’s Voclosporin Misses Superior Tolerability Vs. Restasis, But Pushes On In Dry Eye
Sun Hopes Cequa’s Nano Formulation Makes Big Impact
Ocugen Heads Toward Phase III In Dry Eye With Potential Benefits Over Older Drugs
Deal Watch: Fresenius Buyout Of Akorn Potentially Threatened By Data Integrity Issues
Stock Scan Q4 2017 – Q3 Reporting Chops $70bn From Pharma
Aldeyra's Allergy Drug Misses Endpoint But Company Sees Market Gap
Kala's lead product shows promise in two eye indications

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100033

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel